An increase in splenic volume after first-line immunotherapy is associated with worse PFS in patients with metastatic renal cell carcinoma.
코호트
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
109 patients met inclusion criteria.
I · Intervention 중재 / 시술
first-line ICI treatment and had available abdominal imaging 30 days before and 60-120 days after ICI initiation
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS AND RELEVANCE] In patients with mRCC, a splenic volume increase ≥ 10% at a median of 2.8 months following ICI initiation is independently associated with worse survival compared to an < 10% increase. Monitoring splenic volume changes may serve as a cost-effective radiographic prognostic marker to guide treatment sequencing.
[IMPORTANCE] Reliable prognostic markers for immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC) remain limited.
- p-value P = .022
- p-value P = .002
- 95% CI 1.37-3.96
- 추적기간 25.2 months
- 연구 설계 cohort study
APA
Palmateer G, Yildirim A, et al. (2026). An increase in splenic volume after first-line immunotherapy is associated with worse PFS in patients with metastatic renal cell carcinoma.. The oncologist, 31(2). https://doi.org/10.1093/oncolo/oyaf397
MLA
Palmateer G, et al.. "An increase in splenic volume after first-line immunotherapy is associated with worse PFS in patients with metastatic renal cell carcinoma.." The oncologist, vol. 31, no. 2, 2026.
PMID
41495002
Abstract
[IMPORTANCE] Reliable prognostic markers for immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC) remain limited.
[OBJECTIVE] To examine the impact of splenic volume change after ICI initiation on progression-free survival (PFS) and overall survival (OS) in patients with mRCC.
[DESIGN] A retrospective cohort study reviewing data from 2015 to 2023.
[SETTING] The Emory Kidney Cancer database (single-center academic instution).
[PARTICIPANTS] Patients with mRCC who underwent first-line ICI treatment and had available abdominal imaging 30 days before and 60-120 days after ICI initiation. A total of 109 patients met inclusion criteria.
[EXPOSURE] Splenic volume change calculated as a percentage difference between baseline and follow-up imaging (median 2.8 months post-initiation) using a standardized formula, grouped into ≥10% increase and <10% increase.
[MAIN OUTCOMES AND MEASURES] Differences in OS and PFS assessed using Kaplan-Meier curves and multivariable Cox hazards regression models.
[RESULTS] A total of 109 patients met inclusion criteria. Median follow-up time was 25.2 months (IQR 11.2-41.5), during which there were 47 mortality events. Patients with a splenic volume increase ≥ 10% at a median 2.8 months after ICI initiation had worse 2-year PFS (28.5% vs 50.4%, P = .022) but not OS (69.4% vs 77.8%, P = .853) compared to patients with a < 10% increase in splenic volume. On multivariable analysis, a splenic volume increase ≥ 10% was independently associated with worse PFS (2.33 [95% CI 1.37-3.96], P = .002).
[CONCLUSIONS AND RELEVANCE] In patients with mRCC, a splenic volume increase ≥ 10% at a median of 2.8 months following ICI initiation is independently associated with worse survival compared to an < 10% increase. Monitoring splenic volume changes may serve as a cost-effective radiographic prognostic marker to guide treatment sequencing.
[OBJECTIVE] To examine the impact of splenic volume change after ICI initiation on progression-free survival (PFS) and overall survival (OS) in patients with mRCC.
[DESIGN] A retrospective cohort study reviewing data from 2015 to 2023.
[SETTING] The Emory Kidney Cancer database (single-center academic instution).
[PARTICIPANTS] Patients with mRCC who underwent first-line ICI treatment and had available abdominal imaging 30 days before and 60-120 days after ICI initiation. A total of 109 patients met inclusion criteria.
[EXPOSURE] Splenic volume change calculated as a percentage difference between baseline and follow-up imaging (median 2.8 months post-initiation) using a standardized formula, grouped into ≥10% increase and <10% increase.
[MAIN OUTCOMES AND MEASURES] Differences in OS and PFS assessed using Kaplan-Meier curves and multivariable Cox hazards regression models.
[RESULTS] A total of 109 patients met inclusion criteria. Median follow-up time was 25.2 months (IQR 11.2-41.5), during which there were 47 mortality events. Patients with a splenic volume increase ≥ 10% at a median 2.8 months after ICI initiation had worse 2-year PFS (28.5% vs 50.4%, P = .022) but not OS (69.4% vs 77.8%, P = .853) compared to patients with a < 10% increase in splenic volume. On multivariable analysis, a splenic volume increase ≥ 10% was independently associated with worse PFS (2.33 [95% CI 1.37-3.96], P = .002).
[CONCLUSIONS AND RELEVANCE] In patients with mRCC, a splenic volume increase ≥ 10% at a median of 2.8 months following ICI initiation is independently associated with worse survival compared to an < 10% increase. Monitoring splenic volume changes may serve as a cost-effective radiographic prognostic marker to guide treatment sequencing.
MeSH Terms
Humans; Male; Female; Carcinoma, Renal Cell; Retrospective Studies; Kidney Neoplasms; Middle Aged; Spleen; Aged; Immunotherapy; Progression-Free Survival; Prognosis; Immune Checkpoint Inhibitors